Hepatic arterial infusion chemotherapy (HAIC) significantly improves survival outcomes in advanced hepatocellular carcinoma vs. transarterial chemoembolization (TACE).

• HAIC improves overall survival (OS) by 49% and progression-free survival (PFS) by 45%.
• Key prognostic factors for better outcomes with HAIC include male gender, AFP <400 ng/ml, vascular invasion, and HBV positivity.

Consider HAIC especially for patients with poor prognostic indicators to enhance therapeutic strategies.

• In patients over 60 years, HAIC shows a 33% better PFS compared to TACE.